ArticleMolecular cancer therapeutics2013

Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.

Tian Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.